Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07290569) titled 'Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis' on Dec. 16, 2025.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Oruka Therapeutics, Inc.

Condition: Plaque Psoriasis

Intervention: Drug: ORKA-001

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: December 3, 2025

Target Sample Size: 160

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07290569

Disclaim...